Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413027 | 0.81 | SMN1; SMN2 (0.39) | MMESMN1; SMN2 | |
| SCHEMBL1728121 | 0.77 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL3020915 | 0.75 | TP53 (0.36) | TP53SMN1; SMN2 | |
| SCHEMBL1833108 | 0.74 | — | — | |
| SCHEMBL225761 | 0.74 | — | — | |
| SCHEMBL9764287 | 0.73 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL26939374 | 0.73 | TP53 (0.35) | TP53 | |
| SCHEMBL984063 | 0.71 | TSHR (0.36) | SMN1; SMN2 | |
| SCHEMBL8712260 | 0.71 | TP53 (0.42) | TP53SMN1; SMN2 | |
| SCHEMBL36130 | 0.71 | TP53 (0.42) | TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11480577-B2 | Biopsy methods and devices | INDICATOR SYSTEMS INTERNATIONAL, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-10753942-B2 | Methods to detect remnant cancer cells | INDICATOR SYSTEMS INTERNATIONAL, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200150127-A1 | BIOPSY METHODS AND DEVICES | INDICATOR SYSTEMS INTERNATIONAL, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190107543-A1 | METHODS TO DETECT REMNANT CANCER CELLS | INDICATOR SYSTEMS INTERNATIONAL, INC. (US) | 2019-04-11 | — | — | US | disclosed |
| US-10239891-B2 | Compositions to detect remnant cancer cells | INDICATOR SYSTEMS INTERNATIONAL, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180328933-A1 | BIOPSY METHODS AND DEVICES | INDICATOR SYSTEMS INTERNATIONAL, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180327424-A1 | COMPOSITIONS TO DETECT REMNANT CANCER CELLS | INDICATOR SYSTEMS INTERNATIONAL, INC. | 2018-11-15 | — | — | US | disclosed |
| US-9926334-B1 | — | — | 2018-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11480577-B2 | Biopsy methods and devices | MKI67, RNASE1, CD63 | TP53 13/4885SLC1A3 4813/4885SLC1A2 4863/4885 |
| US-20180327424-A1 | COMPOSITIONS TO DETECT REMNANT CANCER CELLS | MKI67, TP53, RNASE1 | TP53 2/4885SLC1A3 4876/4885SLC1A2 4872/4885 |
| US-10239891-B2 | Compositions to detect remnant cancer cells | MKI67, TP53, RNASE1 | TP53 2/4885SLC1A3 4876/4885SLC1A2 4872/4885 |
| US-20180328933-A1 | BIOPSY METHODS AND DEVICES | MKI67, RNASE1, CD63 | TP53 13/4885SLC1A3 4813/4885SLC1A2 4863/4885 |
| US-20200150127-A1 | BIOPSY METHODS AND DEVICES | MKI67, RNASE1, CD63 | TP53 13/4885SLC1A3 4813/4885SLC1A2 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.